IL144866A0 - N- [2-hydroxy-3- (1-piperidinyl) propoxy] pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance - Google Patents
N- [2-hydroxy-3- (1-piperidinyl) propoxy] pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistanceInfo
- Publication number
- IL144866A0 IL144866A0 IL14486600A IL14486600A IL144866A0 IL 144866 A0 IL144866 A0 IL 144866A0 IL 14486600 A IL14486600 A IL 14486600A IL 14486600 A IL14486600 A IL 14486600A IL 144866 A0 IL144866 A0 IL 144866A0
- Authority
- IL
- Israel
- Prior art keywords
- insulin resistance
- piperidinyl
- propoxy
- pyridine
- hydroxy
- Prior art date
Links
- 206010022489 Insulin Resistance Diseases 0.000 title abstract 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 4
- SGEIEGAXKLMUIZ-PEZBUJJGSA-N (3z)-n-(2-hydroxy-3-piperidin-1-ylpropoxy)-1-oxidopyridin-1-ium-3-carboximidoyl chloride Chemical compound C1CCCCN1CC(O)CO\N=C(/Cl)C1=CC=C[N+]([O-])=C1 SGEIEGAXKLMUIZ-PEZBUJJGSA-N 0.000 title abstract 2
- 230000001575 pathological effect Effects 0.000 abstract 4
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 230000035771 neuroregeneration Effects 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU9900475A HUP9900475D0 (en) | 1999-02-26 | 1999-02-26 | O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component |
| PCT/HU2000/000015 WO2000050403A1 (en) | 1999-02-26 | 2000-02-24 | N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL144866A0 true IL144866A0 (en) | 2002-06-30 |
Family
ID=90014224
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14486600A IL144866A0 (en) | 1999-02-26 | 2000-02-24 | N- [2-hydroxy-3- (1-piperidinyl) propoxy] pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance |
| IL144866A IL144866A (en) | 1999-02-26 | 2001-08-13 | N - [2 - Hydroxy - 3 - (1 - piperidinyl) propoxy] Pyridine - 1 - Oxide - 3 - Carboxymidoyl chloride and its uses in the treatment of insulin resistance |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL144866A IL144866A (en) | 1999-02-26 | 2001-08-13 | N - [2 - Hydroxy - 3 - (1 - piperidinyl) propoxy] Pyridine - 1 - Oxide - 3 - Carboxymidoyl chloride and its uses in the treatment of insulin resistance |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6649628B1 (ja) |
| EP (1) | EP1163224B1 (ja) |
| JP (1) | JP4689838B2 (ja) |
| KR (1) | KR100676124B1 (ja) |
| AT (1) | ATE237590T1 (ja) |
| AU (1) | AU779096B2 (ja) |
| BG (1) | BG65178B1 (ja) |
| BR (1) | BR0008969A (ja) |
| CA (1) | CA2360451C (ja) |
| CZ (1) | CZ297386B6 (ja) |
| DE (1) | DE60002187T2 (ja) |
| DK (1) | DK1163224T3 (ja) |
| EE (1) | EE04961B1 (ja) |
| ES (1) | ES2193055T3 (ja) |
| HR (1) | HRP20010584B1 (ja) |
| HU (1) | HUP9900475D0 (ja) |
| IL (2) | IL144866A0 (ja) |
| NO (1) | NO319793B1 (ja) |
| PL (1) | PL197692B1 (ja) |
| PT (1) | PT1163224E (ja) |
| RS (1) | RS50083B (ja) |
| RU (1) | RU2250901C2 (ja) |
| SI (1) | SI1163224T1 (ja) |
| SK (1) | SK287063B6 (ja) |
| UA (1) | UA72495C2 (ja) |
| WO (1) | WO2000050403A1 (ja) |
| ZA (1) | ZA200106488B (ja) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0001583A2 (hu) | 2000-04-18 | 2002-11-28 | BIOREX Kutató és Fejlesztő Rt. | Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké |
| HU0103939D0 (en) * | 2001-09-27 | 2001-11-28 | Biorex Kutato Fejlesztoe Kft | Pharmaceutical composition containing methformin and n-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride |
| PL371251A1 (en) * | 2002-01-11 | 2005-06-13 | Biorex Kutato Es Fejlesztö Rt. | Carboxamidine derivatives and their use in the treatment of vascular diseases |
| HUP0303584A3 (en) | 2003-10-30 | 2009-12-28 | Cytrx Corp | Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases |
| US20080227813A1 (en) * | 2006-09-26 | 2008-09-18 | Jack Raymond Barber | Pharmaceutical compositions and methods for treating diseases associated with neurodegeneration |
| PL2659904T3 (pl) | 2008-06-26 | 2016-01-29 | Orphazyme Aps | Zastosowanie Hsp70 jako regulatora aktywności enzymatycznej |
| BRPI0919867A2 (pt) * | 2008-11-18 | 2015-12-15 | Santen Pharmaceutical Co Ltd | agente terapeutico ou profilatico para uma doenca degenerativa coriorretiniana, e metodo profilatico ou terapeutico para uma doenca degenerativa coriorrentiniana |
| PL2646044T3 (pl) | 2010-11-30 | 2020-03-31 | Orphazyme A/S | Sposoby zwiększenia aktywności wewnątrzkomórkowej Hsp70 |
| HUP1100534A2 (en) | 2011-09-26 | 2013-04-29 | Balazs Dr Hazay | Pharmaceutical composition for the treatment of muscle atrophy |
| HUP1100535A2 (en) | 2011-09-26 | 2013-04-29 | Bracelia Invest Ltd | Pharmaceutical composition for enhancement of stem cell treatment |
| ES2691981T3 (es) * | 2012-09-06 | 2018-11-29 | Mcpharma Biotech Inc. | Tratamiento de la diarrea y de la diarrea post-destete con almidón resistente de patata |
| CA2884777C (en) | 2012-09-14 | 2018-02-27 | Saint-Gobain Glass France | Pane with an electrical connection element |
| WO2015015248A1 (en) * | 2013-07-30 | 2015-02-05 | Debreceni Egyetem 67% | The use of compounds showing heat shock protein (hsp) co-inducing properties to enhance the insulin sensitizing effect in the treatment of type 2 diabetes |
| EP3922242A1 (en) * | 2014-09-15 | 2021-12-15 | Orphazyme A/S | Arimoclomol formulation |
| US10898476B2 (en) | 2016-04-13 | 2021-01-26 | Orphazyme A/S | Heat shock proteins and cholesterol homeostasis |
| EP3782624A1 (en) * | 2016-04-29 | 2021-02-24 | Orphazyme A/S | Arimoclomol for treating glucocerebrosidase associated disorders |
| AU2018274176A1 (en) | 2017-05-24 | 2020-01-16 | Zevra Denmark A/S | Heat shock protein inducers and frontotemporal disorders |
| BR112020024182A2 (pt) | 2018-05-28 | 2021-03-30 | Orphazyme A/S | Métodos para detectar proteína de choque térmico 70, para diagnosticar uma doença apresentando um nível reduzido de proteína de choque térmico 70, para selecionar um paciente tendo uma doença apresentando um nível reduzido de hsp70, para monitorar progressão de doença em um indivíduo, para monitorar a eficácia de uma terapia para tratamento de uma doença, e, para ajustar a dosagem de um derivado de hidroxilamina de molécula pequena. |
| HUP1800298A1 (hu) | 2018-08-30 | 2020-05-28 | N Gene Res Laboratories Inc | Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére |
| WO2021116487A1 (en) | 2019-12-13 | 2021-06-17 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of niemann-pick c disease |
| CN116075305A (zh) | 2020-06-24 | 2023-05-05 | 柯姆药物丹麦股份公司 | 用于治疗戈谢病的阿瑞洛莫 |
| EP4247792A1 (en) | 2020-11-19 | 2023-09-27 | Zevra Denmark A/S | Processes for preparing arimoclomol citrate and intermediates thereof |
| US20240115558A1 (en) | 2020-12-24 | 2024-04-11 | Zevra Denmark A/S | Arimoclomol for the treatment of niemann pick disease, type c, in patients with er type missense mutations |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU207988B (en) * | 1988-10-20 | 1993-07-28 | Biorex Kutato Fejlesztoe Kft | Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components |
| HU222994B1 (hu) * | 1995-11-02 | 2004-01-28 | BIOREX Kutató és Fejlesztő Rt. | Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására |
| HUT78138A (hu) * | 1995-12-22 | 2000-09-28 | BIOREX Kutató és Fejlesztő Rt | Hidroximsavszármazékot tartalmazó készítmény a növénytermesztés elősegítésére és alkalmazása |
| UA64716C2 (en) * | 1996-08-09 | 2004-03-15 | Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells | |
| HU220971B1 (hu) * | 1997-04-03 | 2002-07-29 | BIOREX Kutató és Fejlesztő Rt. | Eljárás 0-(3-amino-2-hidroxi-propil)-hidroximsav-halogenidek előállítására |
| HUP0001583A2 (hu) * | 2000-04-18 | 2002-11-28 | BIOREX Kutató és Fejlesztő Rt. | Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké |
-
1999
- 1999-02-26 HU HU9900475A patent/HUP9900475D0/hu unknown
-
2000
- 2000-02-24 UA UA2001085933A patent/UA72495C2/uk unknown
- 2000-02-24 AU AU31824/00A patent/AU779096B2/en not_active Expired
- 2000-02-24 ES ES00909542T patent/ES2193055T3/es not_active Expired - Lifetime
- 2000-02-24 WO PCT/HU2000/000015 patent/WO2000050403A1/en active IP Right Grant
- 2000-02-24 PL PL350915A patent/PL197692B1/pl unknown
- 2000-02-24 US US09/913,263 patent/US6649628B1/en not_active Expired - Lifetime
- 2000-02-24 PT PT00909542T patent/PT1163224E/pt unknown
- 2000-02-24 KR KR1020017010932A patent/KR100676124B1/ko not_active IP Right Cessation
- 2000-02-24 IL IL14486600A patent/IL144866A0/xx active IP Right Grant
- 2000-02-24 EP EP00909542A patent/EP1163224B1/en not_active Expired - Lifetime
- 2000-02-24 AT AT00909542T patent/ATE237590T1/de active
- 2000-02-24 CA CA2360451A patent/CA2360451C/en not_active Expired - Lifetime
- 2000-02-24 SK SK1158-2001A patent/SK287063B6/sk not_active IP Right Cessation
- 2000-02-24 CZ CZ20013053A patent/CZ297386B6/cs not_active IP Right Cessation
- 2000-02-24 DK DK00909542T patent/DK1163224T3/da active
- 2000-02-24 EE EEP200100447A patent/EE04961B1/xx not_active IP Right Cessation
- 2000-02-24 RU RU2001126126/04A patent/RU2250901C2/ru active
- 2000-02-24 RS YUP-603/01A patent/RS50083B/sr unknown
- 2000-02-24 BR BR0008969-9A patent/BR0008969A/pt not_active IP Right Cessation
- 2000-02-24 DE DE60002187T patent/DE60002187T2/de not_active Expired - Lifetime
- 2000-02-24 SI SI200030080T patent/SI1163224T1/xx unknown
- 2000-02-24 JP JP2000600986A patent/JP4689838B2/ja not_active Expired - Lifetime
-
2001
- 2001-08-07 HR HR20010584A patent/HRP20010584B1/xx not_active IP Right Cessation
- 2001-08-07 ZA ZA200106488A patent/ZA200106488B/xx unknown
- 2001-08-13 IL IL144866A patent/IL144866A/en not_active IP Right Cessation
- 2001-08-22 BG BG105837A patent/BG65178B1/bg unknown
- 2001-08-23 NO NO20014103A patent/NO319793B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200106488B (en) | N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance. | |
| GB0223038D0 (en) | Therapeutic compounds | |
| GB0225474D0 (en) | Therapeutic agents | |
| MY145590A (en) | Phenylacetamides and their use as glucokinase modulators | |
| DE59410052D1 (de) | Verwendung von nona- und dekapeptiden zur herstellung eines arzneimittels zur bekämpfung von aids | |
| CA2361834A1 (en) | Offset ablation profiles for treatment of irregular astigmatism | |
| NZ504258A (en) | Exendin 3 and 4 agonist compounds for the treatment of diabetes | |
| IL138723A0 (en) | Antitumor agent | |
| HK1086489A1 (en) | A nutrient pharmaceutical formulation comprising polyphenols and use in the manufacture of a medicament for the treatment of cancer | |
| WO1999063977A3 (en) | Pharmaceutical combination comprising a tricyclic compound and at least one of zolpidem, zopiclone, triazolam and brotizolam for treating or preventing sleep disorders | |
| RU2001126126A (ru) | N-[2-гидрокси-3-(1-пиперидинил)пропокси]пиридин-1-оксид-3-карбоксиимидоилхлорид и его применение при лечении невосприимчивости к инсулину | |
| SE0102147D0 (sv) | New methods | |
| UA72927C2 (uk) | Композиція для лікування печінково-клітинного раку, що містить доцетаксель | |
| GEP20105095B (en) | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents | |
| HK1045524B (zh) | 具有抗痴呆作用的5-羥皂草苷配基衍生物 | |
| TNSN99138A1 (fr) | Une composition antioxydante, cytostatique et a support energetique qui ameliore l'utilisation metabolique du glucose | |
| AU3600199A (en) | A pharmaceutical composition containing ezrin mutated on tyrosine 353 | |
| MXPA04010816A (es) | Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares. | |
| MY129832A (en) | Substituted thiophenes, processes for their preparation, their use as medicament or diagnostic and medicament comprising them | |
| TR200101980T2 (tr) | Arilalkanoil türevleri, bunların preparasyon işlemleri | |
| ZA200102727B (en) | Method of treating sickle cell disease or thalassemia. | |
| WO2002076393A3 (en) | Antiagionecic, antitumor, chemopreventative agents | |
| HK1050203A1 (en) | Novel fusidic acid derivatives. | |
| MXPA05014081A (es) | Derivados de benzofurano y su uso en el tratamiento de infecciones microbianas. | |
| AU1195497A (en) | Use of alpha,alpha-diphenylacetic acid-4-(n-methyl-piperidyl)ester as anti-spasmodic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |